Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation

Psychiatry Res. 2025 Mar:345:116377. doi: 10.1016/j.psychres.2025.116377. Epub 2025 Jan 26.

Abstract

Background: Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect of ketamine remains unknown. According to previous research, low-dose ketamine affects large-scale brain networks, including default-mode and salient networks.

Methods: A total of 43 patients with treatment-resistant depression (TRD) and suicidal ideation (SI) were randomly assigned to receive a single infusion of either 0.5 mg/kg ketamine or 0.045 mg/kg midazolam. Depressive and suicidal symptoms were evaluated using the 17-item Hamilton Depression Rating Scale and the Columbia-Suicide Severity Rating Scale: Ideation Severity Subscale. Resting-state functional magnetic resonance imaging was performed at baseline and on day 3 after infusion. Graph theoretic metrics such as degree centrality and clustering coefficient were examined.

Results: Relative to midazolam use, low-dose ketamine infusion reduced depressive (p = 0.001) and suicidal (p = 0.025) symptoms and improved the brain network integrity, including increased degree centrality and clustering coefficient in the angular gyrus and increased degree centrality in the right thalamus.

Discussion: Neurofunctional changes in the thalamus and default-mode network (angular gyrus) may be associated with the antidepressant effect of ketamine on patients with TRD and SI.

Clinical trials registration: UMIN Clinical Trials Registry (UMIN-CTR): Registration number: UMIN000033916.

Keywords: Functional connectivity; Graph theory; Ketamine; Suicidal ideation; Treatment-resistant depression.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antidepressive Agents* / administration & dosage
  • Antidepressive Agents* / pharmacology
  • Brain* / diagnostic imaging
  • Brain* / drug effects
  • Brain* / physiopathology
  • Default Mode Network* / diagnostic imaging
  • Default Mode Network* / drug effects
  • Default Mode Network* / physiopathology
  • Depressive Disorder, Treatment-Resistant* / diagnostic imaging
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Depressive Disorder, Treatment-Resistant* / physiopathology
  • Female
  • Humans
  • Ketamine* / administration & dosage
  • Ketamine* / pharmacology
  • Magnetic Resonance Imaging
  • Male
  • Midazolam / administration & dosage
  • Midazolam / pharmacology
  • Middle Aged
  • Nerve Net* / diagnostic imaging
  • Nerve Net* / drug effects
  • Nerve Net* / physiopathology
  • Suicidal Ideation*

Substances

  • Ketamine
  • Midazolam
  • Antidepressive Agents